封面
市場調查報告書
商品編碼
1496877

全球血型分型市場 - 2024-2031

Global Blood Group Typing Market - 2024-2031

出版日期: | 出版商: DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

司機

需要輸血的道路事故、緊急情況和創傷病例數量不斷增加

全球血型分型市場的需求是由多種因素所驅動的。促進因素之一是需要輸血的道路事故、緊急情況和創傷病例數量的增加,這是血型定型市場的重要驅動力。

道路事故和外傷病例通常會導致嚴重傷害、失血性休克和慢性貧血,可能需要進行大手術。在這種情況下,輸血對於確保患者的生存至關重要。

此外,該行業的主要參與者推出新產品和創新應用程式將推動該市場的成長。根據國家輸血委員會 2024 年 6 月的消息,Transfusion 推出了新的輸血培訓中心,專門為所有從事輸血工作的醫療保健專業人員以及任何希望增加輸血知識的人提供教育和培訓。

同樣,2024 年 2 月,NHS 血液與移植局 (NHSBT) 發布了其首款創新虛擬實境培訓應用程式“NHSBT 血液識別”,該應用程式真實地模擬了用於挽救生命的輸血的血液測試過程。

此外,夥伴關係和協作等關鍵參與者策略將推動該市場的成長。例如,2023 年 3 月,Werfen 完成了對 Immucor, Inc. 的收購,擴大了在專業診斷領域的領導地位。透過此次合作,Werfen 擴大了其為醫院和臨床實驗室提供的診斷解決方案組合。

血型定型產品的高成本、血型定型的複雜性、血液服務基礎設施薄弱、缺乏意識和熟練的專業人員、嚴格的法規以及先進技術的獲取有限等因素預計將阻礙市場的發展。

有關此報告的更多詳細資訊 - 索取樣本

目錄

第 1 章:方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章:定義與概述

第 3 章:執行摘要

  • 按產品分類
  • 技術片段
  • 按測試類型分類的片段
  • 最終使用者的片段
  • 按地區分類的片段

第 4 章:動力學

  • 影響因素
    • 促進要素
      • 需要輸血的道路事故、緊急情況和創傷病例數量不斷增加
      • 產前檢測對血型分型的需求不斷增加
      • 捐血人數不斷增加
    • 限制
      • 血型分型產品的高成本
    • 機會
    • 影響分析

第 5 章:產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 未滿足的需求
  • PESTEL分析
  • 專利分析
  • SWOT分析

第 6 章:COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章:依產品

  • 耗材
  • 儀器
  • 服務

第 8 章:按技術

  • 基於 PCR 的技術
  • 等位基因特異性PCR
  • 即時定量PCR
  • 基於測定的技術
  • 基於微陣列的技術
  • 大規模平行定序

第 9 章:按測試類型

  • ABO 血液檢查
  • 抗原分型
  • 抗體篩選
  • HLA分型
  • 交叉匹配測試

第 10 章:最終用戶

  • 醫院
  • 門診手術中心
  • 血庫
  • 臨床實驗室
  • 其他

第 11 章:按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 12 章:競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 13 章:公司簡介

  • Bio-Rad Laboratories, Inc
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Grifols
  • Thermo Fisher Scientific Inc
  • Agena Bioscience, Inc
  • Bag Diagnostics
  • Lorne Laboratories Limited
  • Tulip Diagnostics
  • DIALAB GmbH
  • Rapid Labs Limited
  • Immucor, Inc

第 14 章:附錄

簡介目錄
Product Code: CD1240

Overview

The global blood group typing market reached US$ 2.08 billion in 2023 and is expected to reach US$ 4.14 billion by 2031, growing at a CAGR of 9.2% during the forecast period 2024-2031.

Blood typing is an important medical service that is used to ensure that patients who are given a transfusion are matched accurately with their blood type.

Currently, patients are routinely tested for ABO blood type to determine if their blood is one of four main types - A, B, AB, or O - and either RhD positive or negative and most patients can be accurately matched with one of these common blood types.

But because of advances in medical science, we now can recognize at least 43 different blood group systems, and it's important, especially for high-risk patients, that blood typing provides a more precise match.

Blood group typing can be classified as forward and reverse typing based on traditional serological testing. Specifically, forward typing involves the detection of A and B antigens based on RBC agglutination by the specific antiserum and the intensity of agglutination, whereas reverse typing is used to identify the presence or absence of anti-A, anti-B, and anti-AB antibodies in plasma or serum.

Market Dynamics

Drivers

Increasing Number of Road Accidents, Emergencies, & Trauma Cases Necessitating Blood Transfusions

The demand for the global blood group typing market is driven by multiple factors. One of the driving factors is the increasing number of road accidents, emergencies, and trauma cases requiring blood transfusions is a significant driver of the blood group typing market.

Road accidents and trauma cases often result in severe injuries, hemorrhagic shock, and chronic anemia, which may require major surgeries. In such situations, blood transfusions are crucial to ensure the patient's survival.

In addition, key players in the industry introducing new launches and innovative apps would drive this market growth. According to the National Blood Transfusion Committee in June 2024, Transfusion introduced the new Transfusion Training Hub, specifically designed to support education and training for all healthcare professionals working with Blood Transfusion and for anyone wishing to increase their transfusion knowledge.

Similarly in February 2024, NHS Blood and Transplant (NHSBT) released its' first innovative virtual reality training app 'NHSBT Blood Identification' which realistically simulates the process of testing blood for lifesaving blood transfusions.

Moreover, key players strategies such as partnerships and collaborations would drive this market growth. For instance, in March 2023, Werfen completed the acquisition of Immucor, Inc., expanding leadership in Specialized Diagnostics. By using this partnership, Werfen expands its portfolio of diagnostic solutions for hospitals and clinical laboratories.

Factors such as the high cost of blood group typing products, the complexity of blood group typing, poor blood services infrastructure, lack of awareness & skilled professionals, stringent regulations, and limited access to advanced technology are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global blood group typing market is segmented based on product, technique, test type, end-user, and region.

The ABO blood tests segment accounted for approximately 23.4% of the global blood group typing market share

The ABO blood tests segment is expected to hold the largest market share over the forecast period. The ABO system is defined by the presence or absence of the A and/or B antigens on human red blood cells and by the presence of antibodies in the plasma or serum corresponding to the antigen or antigens missing in the red blood cells.

Blood groups are usually an individual's combination of antigens on the surface of RBCs, typically of the ABO blood group system and the RH blood group system.

Moreover, key players in the industry introduce innovative technologies that would propel this market growth. For instance, in May 2024, Thermo Fisher Scientific, introduced the Applied Biosystems Axiom BloodGenomiX Array and Software, a first-of-its-kind solution for more precise blood genotyping in clinical research.

The new array covers more than 40 genes and 260 antigens across 38 blood group systems in a single, high-throughput assay. It also detects tissue (HLA) and platelet (HPA) types. Validation studies have demonstrated its accuracy, with a concordance rate of 99.89% with participants' blood group antigen types.

In addition, government initiatives and awareness camps are propelling this segment's growth. As per the Hindu Business Line news in June 2022, the Centre calls for setting up blood group testing camps at all health centers on World Blood Donor Day. Centre calls for setting up blood group testing camps at all health centers on World Blood Donor Day.

Also, in June 2022, in Tamil Nadu, the Directorate of Public Health and Preventive Medicine launched the "Know Your Blood Group" campaign in all PHCs in the state.

Geographical Analysis

North America accounted for approximately 45.4% of the global blood group typing market share

North America region is expected to hold the largest market share over the forecast period. An increase in the number of road accidents and the rising prevalence of chronic diseases are the major factors driving the growth of the market.

In this region, advanced healthcare structure, government awareness programs, and partnerships and collaborations would drive this market growth. For instance, in January 2024, Mayor Muriel Bowser and the District of Columbia Fire and EMS Department announced the Whole Blood Program, an initiative designed to support and train paramedics in performing pre-hospital blood transfusions in partnership with the American Red Cross.

The Whole Blood Program is designed to increase survival rates and clinical outcomes for patients suffering from traumatic injuries, hemorrhagic shock, or severe bleeding by decreasing the amount of time it takes to replace lost blood.

Furthermore, there is an increasing demand for blood transfusion in the United States driving the market growth. According to U.S. blood supply facts in 2024, every 2 seconds someone in the U.S. needs blood and or platelets. Approximately 29,000 units of red blood cells are needed every day in the U. S. Nearly 5,000 units of platelets and 6.500 units of plasma are needed daily in the U.S.

Nearly 16 million blood components are transfused each year in the U.S. Sickle cell disease affects 90,000 to 100,000 people in the U.S. About 1,000 babies are born with the disease each year. Sickle cell patients can require blood transfusions throughout their lives.

Market Segmentation

By Product

  • Consumables
  • Instruments
  • Services

By Technique

  • PCR-based Techniques
    • Allele-specific PCR
    • Real-time PCR
  • Assay-based Techniques
  • Microarray-based Techniques
  • Massively Parallel Sequencing

By Test Type

  • ABO Blood Tests
  • Antigen Typing
  • Antibody Screening
  • HLA Typing
  • Cross Matching Tests

By End User

  • Hospitals
  • Blood Banks
  • Clinical Laboratories
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the blood group typing market include Bio-Rad Laboratories, Inc., Grifols, Thermo Fisher Scientific Inc., Agena Bioscience, Inc., Bag Diagnostics, Lorne Laboratories Limited, Tulip Diagnostics, DIALAB GmbH, Rapid Labs Limited, and Immucor, Inc, among others.

Key Developments

  • In May 2023, Bio-Rad Laboratories, Inc. announced the launch of the IH-500TM NEXT System, a fully automated system for ID cards. The IH-500 NEXT System not only reduces instrument downtime and increases laboratory productivity, but also provides the flexibility and freedom to use high-performing Bio-Rad Reagent Red Blood Cells (RBCs), as well as the lab's RBCs or third-party Reagent RBCs.
  • In March 2022, Quotient Limited announced the receipt of the CE mark for the extended immunohematology microarray. The CE marking confirms the extended IH microarray meets the requirements of the European Medical Devices directive. The Company's MosaiQ platform offers an all-in-one, fully automated, high-performance solution in blood-testing laboratories and other settings.
  • In September 2022, Scientists from NHS Blood and Transplant (NHSBT) and the University of Bristol discovered a new blood group system, called Er, solving a 30-year-old mystery. The team investigated three known blood group antigens - molecules on the surface of red blood cells that can trigger an attack by the immune system - which did not fit into any known blood group system.

Why Purchase the Report?

  • To visualize the global blood group typing market segmentation based on product, technique, test type, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of global blood group typing market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global blood group typing market report would provide approximately 70 tables, 68 figures, and 183 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product
  • 3.2. Snippet by Technique
  • 3.3. Snippet by Test Type
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Number of Road Accidents, Emergencies, & Trauma Cases Necessitating Blood Transfusions
      • 4.1.1.2. Increasing Demand for Blood Group Typing in Prenatal Testing
      • 4.1.1.3. Rising Number of Blood Donations
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost of Blood Group Typing Products
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Consumables *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Instruments
  • 7.4. Services

8. By Technique

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 8.1.2. Market Attractiveness Index, By Technique
  • 8.2. PCR-based Techniques *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Allele-specific PCR
  • 8.4. Real-time PCR
  • 8.5. Assay-based Techniques
  • 8.6. Microarray-based Techniques
  • 8.7. Massively Parallel Sequencing

9. By Test Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 9.1.2. Market Attractiveness Index, By Test Type
  • 9.2. ABO Blood Tests *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Antigen Typing
  • 9.4. Antibody Screening
  • 9.5. HLA Typing
  • 9.6. Cross Matching Tests

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Ambulatory Surgical Centers
  • 10.4. Blood Banks
  • 10.5. Clinical Laboratories
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. South Korea
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Bio-Rad Laboratories, Inc *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio & Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Grifols
  • 13.3. Thermo Fisher Scientific Inc
  • 13.4. Agena Bioscience, Inc
  • 13.5. Bag Diagnostics
  • 13.6. Lorne Laboratories Limited
  • 13.7. Tulip Diagnostics
  • 13.8. DIALAB GmbH
  • 13.9. Rapid Labs Limited
  • 13.10. Immucor, Inc

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us